{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:59:24Z","timestamp":1761487164267},"reference-count":36,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Between 1999 and 2001, 16,731 isolates from the Asia-Pacific Region were tested in the SENTRY Program for susceptibility to six fluoroquinolones including garenoxacin. Garenoxacin was four- to eightfold less active against\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            than ciprofloxacin, although both drugs inhibited similar percentages at 1 \u03bcg\/ml. Garenoxacin was more active against gram-positive species than all other fluoroquinolones except gemifloxacin. For\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            , oxacillin resistance was high in many participating countries (Japan, 67%; Taiwan, 60%; Hong Kong, 55%; Singapore, 52%), with corresponding high levels of ciprofloxacin resistance (57 to 99%) in oxacillin-resistant\n            <jats:italic>S. aureus<\/jats:italic>\n            (ORSA). Of the ciprofloxacin-resistant ORSA isolates, the garenoxacin MIC was &gt;4 \u03bcg\/ml for only 9% of them. For\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            , penicillin nonsusceptibility and macrolide resistance were high in many countries. No relationship was seen between penicillin and garenoxacin susceptibility, with all isolates being susceptible at &lt;2 \u03bcg\/ml. There was, however, a partial correlation between ciprofloxacin and garenoxacin MICs. For ciprofloxacin-resistant isolates for which garenoxacin MICs were 0.25 to 1 \u03bcg\/liter, mutations in both the ParC and GyrA regions of the quinolone resistance-determining region could be demonstrated. No mutations conferring high-level resistance were detected. Garenoxacin shows useful activity against a wide range of organisms from the Asia-Pacific region. In particular, it has good activity against\n            <jats:italic>S. aureus<\/jats:italic>\n            and\n            <jats:italic>S. pneumoniae<\/jats:italic>\n            , although there is evidence that low-level resistance is present in those organisms with ciprofloxacin resistance.\n          <\/jats:p>","DOI":"10.1128\/aac.48.6.2049-2055.2004","type":"journal-article","created":{"date-parts":[[2004,5,21]],"date-time":"2004-05-21T18:38:42Z","timestamp":1085164722000},"page":"2049-2055","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":17,"title":["Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001"],"prefix":"10.1128","volume":"48","author":[{"given":"K. J.","family":"Christiansen","sequence":"first","affiliation":[{"name":"Royal Perth Hospital, Perth"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Bell","sequence":"additional","affiliation":[{"name":"Women's and Children's Hospital, Adelaide, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. D.","family":"Turnidge","sequence":"additional","affiliation":[{"name":"Women's and Children's Hospital, Adelaide, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. N.","family":"Jones","sequence":"additional","affiliation":[{"name":"The JONES Group\/JMI Laboratories, North Liberty, Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.234-238.2002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00475-7"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00224-3"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2032"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.suppl_3.95"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.971-976.2002"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3351-3356.2000"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.5.1463-1466.2001"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.187"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2165\/00003495-199500492-00007","volume":"49","year":"1995","unstructured":"Goldstein, F. W., and J. F. Acar. 1995. Epidemiology of quinolone resistance: Europe and North and South America. Drugs49(Suppl. 2):36-42.","journal-title":"Drugs"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0732-8893(02)00374-7","volume":"43","year":"2002","unstructured":"Gordon, K. A., M. L. Beach, D. J. Biedenbach, R. N. Jones, P. R. Rhomberg, and A. H. Mutnick. 2002. Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn. Microbiol. Infect. Dis.43:157-162.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/jac\/dkf028","volume":"49","year":"2002","unstructured":"Gordon, K. A., M. A. Pfaller, and R. N. Jones. 2002. BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000). J. Antimicrob. Chemother.49:851-855.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2865-2870.2001"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/jac\/47.5.655","volume":"47","year":"2001","unstructured":"Ho, P. L., W. C. Yam, T. L. Que, D. N. Tsang, W. H. Seto, T. K. Ng, and W. S. Ng. 2001. Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones. J. Antimicrob. Chemother.47:655-658.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.5.659"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3370-3380.2002"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.3.353"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.462-466.2000"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2962-2968.2000"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0732-8893(02)00415-7","volume":"43","year":"2002","unstructured":"Kirby, J. T., A. H. Mutnick, R. N. Jones, D. J. Biedenbach, and M. A. Pfaller. 2002. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol. Infect. Dis.43:303-309.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.191-195.2002"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3346\/jkms.2001.16.3.262","volume":"16","year":"2001","unstructured":"Lee, K., H. S. Lee, S. J. Jang, A. J. Park, M. H. Lee, W. K. Song, and Y. Chong. 2001. Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone. J. Korean Med. Sci.16:262-270.","journal-title":"J. Korean Med. Sci."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3374-3380.2000"},{"key":"e_1_3_2_25_2","unstructured":"NCCLS. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard 5th ed. NCCLS document M7-A5. NCCLS Wayne Pa."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2321"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.251-254.2002"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.2.243"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/49.2.283","volume":"49","year":"2002","unstructured":"Schmitz, F. J., M. Boos, S. Mayer, H. Jagusch, and A. C. Fluit. 2002. Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother.49:283-287.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.934-935.2002"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.4.481"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.1249"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.1999.tb00143.x"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-199500492-00008","volume":"49","year":"1995","unstructured":"Turnidge, J. 1995. Epidemiology of quinolone resistance. Eastern hemisphere. Drugs49(Suppl. 2):43-47.","journal-title":"Drugs"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.1.177"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.242-244.2002"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.7164\/antibiotics.52.75","volume":"52","year":"1999","unstructured":"Yamaguchi, K., A. Ohno, F. Kashitani, M. Iwata, Y. Shimizu, S. Sato, I. Matsumoto, M. Itoh, T. Funato, Y. Tsujio, M. Nagasawa, M. Tachibana, H. Kanno, K. Matsuda, J. Okada, H. Takaya, T. Nakamura, J. Igari, K. Sugimoto, T. Oguri, S. Toyoshima, M. Okada, T. Nakai, M. Kuwabara, Z. Nagasawa, et al. 1999. In vitro activities of 23 antimicrobial agents against 4,993 gram-positive and gram-negative bacterial strains isolated from multicenter of Japan during 1994-in vitro susceptibility surveillance. Levofloxacin-Surveillance Group. Jpn. J. Antibiot.52:75-92.","journal-title":"Jpn. J. Antibiot."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.6.2049-2055.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.6.2049-2055.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:20:16Z","timestamp":1645467616000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.6.2049-2055.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1128\/AAC.48.6.2049-2055.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.6.2049-2055.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]},"assertion":[{"value":"2003-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-02-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}